RNA-based therapeutics, including circular RNA, have gained significant momentum since the COVID-19 pandemic highlighted their potential in vaccine development and other forms of treatment. To date, RNA-based vaccines have garnered much of the spotlight due to their high immunogenicity, rapid development timelines, design flexibility, and higher efficacy against severe disease. However, the broader field of RNA modalities is evolving quickly. To keep pace with this progress, various technologies are being leveraged to evaluate the efficacy and safety of these therapeutic approaches.

In this on-demand webinar, Revvity’s James White, PhD, R&D Assay Development Lead, and Dipti Mehta, Senior Application Scientist, will explore microfluidic platforms for characterizing circular nucleic acids and other major isoforms with a high degree of reproducibility, sensitivity, and throughput.

Covering: 

• New advances and analytical challenges in RNA modalities for therapeutics
• RNA analysis using the LabChip™ GXII Touch™ Characterization system
• Methods for analyzing new RNA modalities
• Plasmid DNA analysis with the LabChip pDNA assay 

For research use only. Not for use in diagnostic procedures.